Literature DB >> 20348146

ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.

T Mizuno1, T Terada1, T Kamba2, M Fukudo1, T Katsura1, E Nakamura2, O Ogawa2, K Inui3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20348146     DOI： 10.1093/annonc/mdq150

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

Review 1.  Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Authors:  Tomohiro Terada; Daiki Hira
Journal:  J Gastroenterol       Date:  2015-03-14       Impact factor: 7.527

2.  Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.

Authors:  K Toyama; A Yonezawa; S Masuda; R Osawa; M Hosokawa; S Fujimoto; N Inagaki; K Inui; T Katsura
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

Authors:  C Narjoz; A Cessot; A Thomas-Schoemann; J L Golmard; O Huillard; P Boudou-Rouquette; A Behouche; F Taieb; J P Durand; A Dauphin; R Coriat; M Vidal; M Tod; J Alexandre; M A Loriot; F Goldwasser; B Blanchet
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

Review 4.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Authors:  K Mandery; H Glaeser; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Authors:  Masahide Fukudo; Yasuaki Ikemi; Yosuke Togashi; Katsuhiro Masago; Young Hak Kim; Tadashi Mio; Tomohiro Terada; Satoshi Teramukai; Michiaki Mishima; Ken-Ichi Inui; Toshiya Katsura
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

6.  Continuous remission of renal cell carcinoma with tumour thrombus after severe adverse events following short-term treatment with sunitinib.

Authors:  Akira Kazama; Akiyoshi Katagiri; Shoko Ishikawa; Takaki Mizusawa
Journal:  BMJ Case Rep       Date:  2017-08-28

7.  Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib.

Authors:  Satoshi Noda; Susumu Kageyama; Teruhiko Tsuru; Shigehisa Kubota; Tetsuya Yoshida; Keisei Okamoto; Yusaku Okada; Shin-Ya Morita; Tomohiro Terada
Journal:  Case Rep Oncol       Date:  2012-09-21

Review 8.  The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.

Authors:  Jose J G Marin; Maria J Monte; Alba G Blazquez; Rocio I R Macias; Maria A Serrano; Oscar Briz
Journal:  Acta Pharmacol Sin       Date:  2013-12-09       Impact factor: 6.150

9.  Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.

Authors:  Yuji Miura; Chiyo K Imamura; Koya Fukunaga; Yoshihiko Katsuyama; Koichi Suyama; Toshikazu Okaneya; Taisei Mushiroda; Yuichi Ando; Toshimi Takano; Yusuke Tanigawara
Journal:  BMC Cancer       Date:  2014-12-16       Impact factor: 4.430

10.  Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.

Authors:  Hiroshi Miyata; Tappei Takada; Yu Toyoda; Hirotaka Matsuo; Kimiyoshi Ichida; Hiroshi Suzuki
Journal:  Front Pharmacol       Date:  2016-12-27       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.